Isofluran Piramal (Isoflurane)

Isoflurane works by enhancing the activity of the inhibitory GABA_A receptor, which increases chloride ion flow and hyperpolarizes neurons. At the same time, it suppresses excitatory pathways such as NMDA receptors, leading to reduced neuronal firing, loss of consciousness, and analgesia.

The dose of Isofluran Piramal is determined by the prescribing clinician based on the patient’s age, weight, surgical requirements, and monitoring parameters. Specific dosing regimens are not disclosed publicly and should follow the prescriber’s instructions.

Safety data for Isofluran Piramal in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order Isofluran Piramal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Isofluran is comparable to other volatile anesthetics such as sevoflurane. While both provide rapid induction and maintenance of anesthesia, Isofluran typically has a lower blood‑gas partition coefficient, which may result in slower emergence compared with sevoflurane, but it is often chosen for its cost‑effectiveness and stable hemodynamic profile.

Isofluran Piramal should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the solution from direct sunlight, moisture, and extreme temperatures. Handling requires standard precautions for volatile anesthetic agents, including use of appropriate vapour‑capture systems in the operating room.

Isofluran Piramal is administered by inhalation using a calibrated vapouriser attached to an anesthesia machine. The solution is vaporised into a carrier gas (usually oxygen or air) and delivered to the patient’s airway, allowing precise control of anesthetic depth.

The most serious risks include malignant hyperthermia, a rare but life‑threatening hypermetabolic reaction; severe hypotension leading to cardiovascular instability; and profound respiratory depression requiring immediate airway support and ventilation management.

Isofluran Piramal should be avoided in patients with known hypersensitivity to isoflurane or other halogenated anesthetics, those with a personal or family history of malignant hyperthermia, and individuals with severe cardiovascular instability where further depression of blood pressure could be hazardous.